Fig. 1

Flowchart of study design and population. Between January 2010 and May 2022, an estimated 5680 patients with hematological malignancies (including acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma, acute lymphoblastic lymphoma, Hodgkin lymphoma, and non-Hodgkin lymphoma) were treated as inpatients at our department of hematology and oncology or department of stem cell transplantation. *Patients with chronic myeloid leukemia and myeloproliferative neoplasia were excluded